Boston Scientific Corporation (BSX) Fell Due to Weak Results

9 hours ago 2

Soumya Eswaran

Wed, May 20, 2026 astatine 8:19 AM CDT 3 min read

TCW Funds, an concern absorption firm, published its first-quarter 2026 capitalist missive for the 'TCW Concentrated Large Cap Growth Fund.' A transcript of the missive is disposable to download here. The archetypal 4th was marked by volatility successful equity markets, driven by geopolitical tensions, concerns astir the backstage recognition sector, a authorities shutdown, and ongoing AI concerns. During this period, The Fund (I Share) reported a nett nonaccomplishment of 11.75%, lagging down the Russell 1000 Growth Index instrumentality of -9.78%. The Fund considers the market's broadening arsenic a steadfast motion and remains assured that the marketplace volition yet admit the portfolio's intrinsic value. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2026.

In its first-quarter 2026 capitalist letter, TCW Concentrated Large Cap Growth Fund highlighted Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) is simply a aesculapian exertion institution that manufactures and markets aesculapian devices for usage successful assorted interventional aesculapian specialties. On May 19, 2026, Boston Scientific Corporation (NYSE:BSX) closed astatine $56.81 per share. One-month instrumentality of Boston Scientific Corporation (NYSE:BSX) was -12.42%, and its shares mislaid 45.71% implicit the past 52 weeks. Boston Scientific Corporation (NYSE:BSX) has a marketplace capitalization of $84.44 billion.

TCW Concentrated Large Cap Growth Fund stated the pursuing regarding Boston Scientific Corporation (NYSE:BSX) successful its Q1 2026 capitalist letter:

"Shares of Boston Scientific Corporation (NYSE:BSX); 2.05%**) moved little during March aft the institution reported disappointing quarterly results successful aboriginal February, and the institution presented information from the highly anticipated CHAMPION-AF proceedings astatine the extremity of March. Though BSX modestly bushed apical and bottom-line statement estimates, the company’s 2 cardinal maturation franchises (U.S. Electrophysiology and Watchman) missed expectations. Management lowered 2026 integrated income maturation guidance to a scope of +10-11%. BSX continues to garner the bulk of income successful electrophysiology, but wide marketplace maturation is decelerating, and contention whitethorn beryllium taking immoderate marketplace share. While Watchman maturation was beardown (+29% organically successful the quarter), results missed statement estimates. The durability and maturation trajectory for Watchman is simply a absorption for investors, and though CHAMPION-AF information released astatine the extremity of the period deed each endpoints, they failed to enactment arsenic a affirmative catalyst for BSX shares. Though we admit the timing and magnitude of WATCHMAN publication whitethorn not beryllium resolved successful the near-term, we judge existent valuation whitethorn person overly discounted the company’s agelong word net maturation profile. As we intimately show the situation, we stay constructive connected shares."

Read Entire Article